FIP in cats was previously a viral infection that was fatal in about 96% of cases. It is caused by a mutation of the feline enteric coronavirus.
Feline enteric coronaviruses are widespread. They lead to Diarrhea, Fever and sometimes Vomiting. The viruses are excreted in the feces. They can be absorbed by other animals via the nasopharyngeal space and lead to infections. Puppies often become infected by their mothers. While the feline enteric coronavirus is transmissible, i.e. there is a risk of infection, the mutated virus responsible for FIP is not transmitted from animal to animal.
The first Symptoms: usually appear a few weeks or 1–2 months after the virus mutates in the body. In rare cases, Symptoms: do not appear until 1-1.5 years later. Genetic and immunological factors contribute to a cat’s susceptibility to FIP.
Each year, approximately 1–2% of all cats become ill.
In more recent studies, a new variant of the FIP virus (subtype) appears to have emerged, which is believed to be responsible for the rapid spread of FIP in Cyprus in 2023. This variant is believed to be transmitted directly from animal to animal.
There is no risk of infection for humans with either type of virus.
But now FIP is curable.
Description of the forms, Symptoms: and stages of FIP
Forms of FIP
Based on the typical Symptoms:, different forms of FIP are distinguished:
Effusive FIP
- Effusion in the abdominal cavity (ascites)
- Effusion in the pleural space of the chest cavity (pleural effusion)
- Fluid accumulation in the scrotum
Non-effusive FIP
- Lethargy
- Loss of appetite
- Weight loss
- Jaundice
Neurologic FIP
- Ataxia, especially affecting the hindquarters
- Seizures
- Behavioral disorders
- Nystagmus
- Epileptiform seizures
- Blindness
- Hyperesthesia
- Head tilt
Ocular FIP
- Inflammation of the iris with color changes of the iris
- Deposits and Bleeding in the anterior chamber of the eye
- Corneal thickening
- Retinal detachment and Blindness
The forms of FIP are not strictly separated. Mixed forms are common. Skin changes, such as slightly raised papules lying in the skin, especially in the area of the neck and on the lateral chest walls, can also occur in connection with FIP. They can easily be overlooked in dense fur. In the case of a disturbed general condition without a recognizable cause, Skin changes should be examined for coronaviruses.
Stages of FIP
FIP is characterized by different stages.
Early stage: Characterized by unspecific signs of illness
- Fever spikes
- Reduced appetite
- Weight loss
- Lethargy
Middle stage: Worsening of the Symptoms: of the early stage, as well as
- Ascites (abdominal dropsy)
- Anemia
- Diarrhea,
- Jaundice (icterus, discoloration of all visible mucous membranes, the skin and the eyeball)
Late stage:
- Loss of appetite (inappetence)
- Coordination disorders
- Paralysis
- Seizures
Diagnosis of FIP
The detection of antibodies in the blood against the coronavirus (Corona-AK titer) does not say anything about the possible presence of FIP. Often the Corona-AK titers are equated with the presence of FIP. That’s not right. The level of the titer also says nothing about whether a cat has FIP or not. Even if no antibodies against the coronavirus can be detected, FIP cannot be ruled out 100%.
A special laboratory test in which viruses can be detected directly in the blood, in effusion fluid or in tissue samples (PCR) helps. The viral load (quantification of the viruses present in the sample) provides further information.
For cases in which the clinical picture is not clear and the viral load in the examined sample is low, there are now also methods (RT-PCR) to detect the mutated form of the Feline Covid virus (FCoV) that causes FIP.
Treatment of Feline Infectious Peritonitis with GS-441524 (GS) and Remdesivir
GS-441524 (GS)
Pedersen (UC Davis School of Veterinary Medicine) published a groundbreaking article in 2019 (1) describing the treatment of cats with FIP with the antiviral drug GS-441524 (GS). GS is a drug that is used in the treatment of the coronavirus infection COVID-19 in humans under certain circumstances.
So far, GS has only been approved in Australia and the UK for the treatment of cats. Through the collaboration of Stokes Pharmacy (USA) and BOVA-Phamaceutics (UK, https://bova.vet/fip-resource-page/?) the drug has also been legally available for cats in the USA since June 1, 2024. GS is offered as a tablet or liquid oral suspension from BOVA.
Remdesivir
Another antiviral agent is Remdesivir. Remdesivir (“Veklury” in Germany) received conditional approval in 2020 and full marketing authorization in the European Union in 2022 (on the Internet: DOI 10.25646/6939.6) for the treatment of Covid-19 in humans.
This means that Remdesivir is available on the German market and can be used “Off Label” (see below).
In the meantime, various international studies have been carried out on the use of these two drugs individually or in combination for the treatment of FIP. The high efficacy of these drugs (86–100%) has been confirmed and optimal treatment protocols have been developed.
In Germany, both drugs are (still) not approved.
Possible access to GS-441524
One way to use this drug is to apply for an import permit to import GS-441524 from abroad, e.g. from the UK.
Here is an interesting link to a message from Bova-Pharmaceuticals on the use of GS in cats with the title: “FIP: So much has changed, where are we now? (2024)” https://bova.vet/2024/04/04/fip-changes/
Possible access to Remdesivir
A possible solution is the use of Remdesivir “Off-Label”, as the drug is approved in Germany for humans. Off Label means “non-intended use”. The drug is used against a disease for which it has no approval from the EMA regulatory authority. In the event of such use, the manufacturer is no longer liable for any damage, but rather the doctor or veterinarian. This must protect himself through a so-called “informed consent” through the animal owner after particularly careful clarification. This means that veterinarians must ensure that pet owners are fully informed about the possible risks and the pet owner must agree in writing. This informed consent is crucial.
It should not be concealed that Remdesivir in human medicine is suspected of promoting the development of mutations in viruses.
The drug Remdesivir for human medicine can only be injected. It has a very low pH, so injections under the skin are painful and can lead to Inflammatory conditions. It would still make sense for the first 7 days of treatment. After that, GS, which is available in tablet form, would be desirable, as the treatment period is at least 12 weeks!
The difficult access to the two therapeutically highly effective drugs GS-441524 (GS) and Remdesivir is disappointing, but do not resort to buying on the black market on the Internet. The actual composition of these drugs cannot be verified. You could invest thousands of dollars in an ineffective drug or, worse, possibly harm your animal.
Treatment protocol
The treatment of FIP lasts 12 weeks. But the cat gets significantly better within a week. It is still essential to continue the twelve-week treatment, as otherwise the virus is not completely eliminated and a relapse is to be expected after the end of the treatment. Close monitoring of the cat during treatment is also important. In some cases, adjustments to the treatment regimen are necessary.
Treatment progress
Day 1–2:
The Fever should subside. The appetite may already return a little. It is possible that the accumulation of fluid in the abdominal cavity and chest will increase slightly.
Day 3–5: Most cats are doing much better. The eye and neurological Symptoms: also subside. The neurological Symptoms: largely subside somewhat.
Day 7: The shortness of breath (dyspnea) usually disappears because the triggering fluid accumulation in the chest (pleural effusion) is absorbed by the body.
Day 7–14: Within this time, the effusion in the abdominal cavity (ascites) is also largely absorbed and the eye Symptoms: are significantly or completely reduced.
Day 21–28: The absorption of the abdominal effusion is complete. The neurological Symptoms: are significantly reduced or no longer present.
Monitoring of the therapy
- Weighing and adjusting the dose: at least weekly. Since the cat starts eating and gaining weight during the therapy and young animals are still growing, the dose must be adjusted. Underdosing endangers the success of the therapy.
- Blood count control: The success of the therapy can be assessed on the basis of the blood count and clinical-chemical values and measures can be taken to optimize it. The control should take place every 4–6 weeks. At least glucose, creatinine, BUN, albumin, globulin, ALT, ALP and total bilirubin should be determined.
- Monitoring clinical Symptoms:: Clinical Symptoms: must be monitored throughout the treatment to ensure that the decrease or disappearance of Symptoms: meets expectations. New Symptoms: may become visible because they were superimposed by the disease state before treatment. This can be the case, for example, with neurological Symptoms:.
Completion of the therapy
To determine whether a patient is ready to complete treatment after 84 days or after a longer treatment, both clinical and diagnostic information must be considered. It is imperative that the overall picture of the cat’s health is taken into account, rather than giving excessive weight to a slightly abnormal value in the blood count. (For example, a slightly high globulin value or a slightly low albumin to globulin ratio.) The cat should be treated, not the blood count!
Blood count
To assess whether treatment can be terminated, a blood count and clinical-chemical values should be determined in the blood serum. Ideally, the usual blood values for FIP should be back in the normal range. More precisely:
- The anemia should be resolved.
- The neutrophil granulocytes should be in the normal range.
- The percentage of lymphocytes should be 20% or more.
- Lymphocytosis is often observed during and after treatment and is the result of immune activation. It can take months to fully normalize.
- Lymphocytosis can be neglected in connection with FIP.
- The hyperbilirubinemia disappears.
- The globulins are in the normal range
An albumin/globulin ratio of 0.7 or higher is desirable, although some cats do not achieve this but can still be considered cured. An A/G value below 0.7 is less of a concern if it is due to normal globulins and low (or low-normal) albumin values and not vice versa.
Blood count and serum chemistry also include numerous other values that can generally be ignored unless they are significantly increased or decreased and are related to clinical Symptoms:.
Unless there are any particular concerns, performing an ultrasound or X-ray at the end of treatment is neither necessary nor recommended. This is because small amounts of abdominal fluid or vague irregularities in organs such as the kidneys, spleen, pancreas or intestines in the end stage in the ultrasound are more likely to be residual findings than signs of active disease.
Clinical assessment
- The cat should be examined for external signs of its health. For example:
- Have the neurological and ocular Symptoms: subsided?
- Keep in mind that neurological and ocular FIP can leave some permanent damage/Symptoms:
- Does the cat have a normal (or above normal) energy level?
- Does the cat have a normal appetite?
- Has the cat gained weight?
If a cat does not essentially meet the above criteria, it is recommended to increase the dosage and extend the treatment by at least 4 weeks.
After completion of the treatment, it is recommended to observe the cat for three months to determine whether the treatment was successful. During this time, a check-up and a blood count are recommended every 4–6 weeks.
As a supportive measure, the additional administration of vitamin B 12 during the treatment makes sense. Vitamin B 12 is needed for the formation of red blood cells. It is contained in particular in animal feed such as meat, inner organs, fish, eggs.
Antiviral resistance
If resistance to the current antiviral agent is suspected, it may be desirable to switch the cat to another antiviral treatment. Antiviral resistance is typically indicated by either a lack of response to the antiviral agent or a pattern of an initial positive response followed by a relapse that persists as the dose is increasingly increased. Aggressive dose increases can sometimes overcome antiviral resistance, but high doses can make administration difficult and make alternative antiviral therapies more attractive.
If treatment is unsuccessful, a trial with a higher dosage (or an alternative antiviral agent) can be performed for two weeks. The cat is then examined again. If the symptoms or laboratory findings do not improve, you can more confidently conclude that they are not caused by active FIP and discontinue treatment. If improvement occurs, treatment should be extended for at least two more weeks.
Possible side effects
Side effects are relatively rare and usually mild. They primarily consist of Inflammatory conditions at the injection site. With the use of GS, Diarrhea and Vomiting have been observed in some cases. Sometimes, fatigue and loss of appetite can also occur. Changes in liver and kidney values are possible in the blood.
Sources
1 Pedersen N. C., Perron M., Bannasch M., Montgomery E., Murakami E., Liepnieks M., & Liu H. (2019). Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. Journal of Feline Medicine and Surgery, 21(4), 271–281. https://doi.org/10.1177/1098612X19825701
2 Taylor S, Coggins S, Tasker S et al. (2023): Retrospective study and outcome of 307 cats with feline infectious peritonitis treated with legally sourced veterinary compounded preparations of remdesivir and GS-441524 (2020–2022). J Feline Med Surg 25(9). doi.org/10.1177/1098612X231194460.
3 FIP: So much has changed, where are we now? (2024)“ https://bova.vet/2024/04/04/fip-changes/ 2024)“